Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218166 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00218166 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 78 participants.
The verdict
NCT00218166, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
Cocaine abuse continues to represent a significant public-health concern. Cocaine likely creates its addictive effects by increasing levels of dopamine, a chemical found in the brain. GABA agonists are chemicals that have the opposite effect of cocaine by inhibiting the release of dopamine. The purpose of this study is to determine whether GABA agonists reduce the psychological and physiological reinforcing effects of cocaine.
Interventions
- DRUG GABA Agonists
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2001-08 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218166
The ClinicalTrials.gov registry entry for NCT00218166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GABA Agonists is the first listed.
NCT00218166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218166 about?
NCT00218166 is a clinical study titled "Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine". Cocaine abuse continues to represent a significant public-health concern. Cocaine likely creates its addictive effects by increasing levels of dopamine, a chemical found in the brain. GABA agonists are chemicals that have the opposite effect of cocaine by inhibiting the release of dopamine. The purp...
What is the current status of trial NCT00218166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2001-08. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00218166?
The interventions under investigation include: GABA Agonists (DRUG).
Who is sponsoring clinical trial NCT00218166?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.